.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,993,761

« Back to Dashboard

Claims for Patent: 8,993,761

Title:Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Inventor(s): Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Tokushima, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Tokushima, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Tokushima, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Tokushima, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Toksuhima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee: Otsuka Pharamceutical Co. Ltd. (Tokyo, JP)
Application Number:13/749,753
Patent Claims: 1. Hydrate A of aripiprazole having an endothermic curve comprising a first endothermic peak at about 71.degree. C. and a second endothermic peak around 60.degree. C. to 120.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min).

2. The Hydrate A of aripiprazole according to claim 1, wherein said Hydrate A of aripiprazole has a mean particle size of 50 .mu.m or less.

3. The Hydrate A of aripiprazole according to claim 1, wherein said Hydrate A of aripiprazole has a mean particle size of 20 .mu.m or less.

4. The Hydrate A of aripiprazole according to claim 1, wherein said Hydrate A of aripiprazole has a mean particle size of 36-14 .mu.m.

5. Hydrate A of aripiprazole having an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 1.

6. The Hydrate A of aripiprazole according to claim 5, wherein said Hydrate A of aripiprazole has a mean particle size of 50 .mu.m or less.

7. The Hydrate A of aripiprazole according to claim 5, wherein said Hydrate A of aripiprazole has a mean particle size of 20 .mu.m or less.

8. The Hydrate A of aripiprazole according to claim 5, wherein said Hydrate A of aripiprazole has a mean particle size of 36-14 .mu.m.

9. The Hydrate A of aripiprazole according to any one of claims 2-4 and 6-8, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

10. The Hydrate A of aripiprazole according to claim 9, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said Hydrate A of aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

11. Hydrous aripiprazole having an endothermic curve comprising a first endothermic peak at about 71.degree. C. and a second endothermic peak around 60.degree. C. to 120.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) and one or more of the following properties: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree., 15.4.degree., 17.3.degree., 18.0.degree., 18.6.degree., 22.5.degree., and 24.8.degree. using a Cu K.sub..alpha. x-ray; and an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963, and 784 cm.sup.-1 on the IR (KBr) spectrum.

12. The hydrous aripiprazole according to claim 11, wherein said hydrous aripiprazole has a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree., 15.4.degree., 17.3.degree., 18.0.degree., 18.6.degree., 22.5.degree., and 24.8.degree. using a Cu K.sub..alpha. x-ray.

13. The hydrous aripiprazole according to claim 11, wherein said hydrous aripiprazole has an infrared absorption spectrum comprising infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963, and 784 cm.sup.-1 on the IR (KBr) spectrum.

14. Hydrous aripiprazole having an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 1.

15. The hydrous aripiprazole according to claim 14, having a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 3 using a Cu K.sub..alpha. x-ray.

16. The hydrous aripiprazole according to any one of claims 11 to 15, wherein said hydrous aripiprazole has a mean particle size of 50 .mu.m or less.

17. The hydrous aripiprazole according to claim 16, wherein said hydrous aripiprazole has a mean particle size of 20 .mu.m or less.

18. The hydrous aripiprazole according to claim 16, wherein said hydrous aripiprazole wherein said hydrous aripiprazole has a mean particle size of 36-14 .mu.m.

19. The hydrous aripiprazole according to claim 16, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

20. The hydrous aripiprazole according to claim 17, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

21. The hydrous aripiprazole according to claim 18, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

22. The hydrous aripiprazole according to claim 16, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

23. The hydrous aripiprazole according to claim 17, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

24. The hydrous aripiprazole according to claim 18, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

25. Hydrous aripiprazole made by a process comprising milling a hydrate of aripiprazole having one or more of the following properties: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree., 15.1.degree., 17.4.degree., 18.2.degree., 18.7.degree., 24.8.degree., and 27.5.degree. using a Cu K.sub..alpha. x-ray; and an endothermic curve comprising endothermic peaks at 75.0.degree. C., 123.5.degree. C., and 140.5.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min), to a mean particle size of 50 .mu.m or less.

26. The hydrous aripiprazole according to claim 25, wherein said hydrate of aripiprazole has a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree., 15.1.degree., 17.4.degree., 18.2.degree., 18.7.degree., 24.8.degree., and 27.5.degree. using a Cu K.sub..alpha. x-ray.

27. The hydrous aripiprazole according to claim 25, wherein said hydrate of aripiprazole has an endothermic curve comprising endothermic peaks at 75.0.degree. C., 123.5.degree. C., and 140.5.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min).

28. Hydrous aripiprazole made by a process comprising milling a hydrate of aripiprazole having one or more of the following properties: a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 7 using a Cu K.sub..alpha. x-ray; and an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 6, to a mean particle size of 50 .mu.m or less.

29. The hydrous aripiprazole according to claim 28, wherein said hydrate of aripiprazole has a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 7 using a Cu K.sub..alpha. x-ray.

30. The hydrous aripiprazole according to claim 28, wherein said hydrate of aripiprazole has an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 6.

31. The hydrous aripiprazole according to any one of claims 25-30, wherein said milling is performed by an atomizer using a rotational speed of 5000-15000 rpm for the main axis, a feed rotation of 10-30 rpm and a screen hole size of 1-5 mm.

32. The hydrous aripiprazole according to any one of claims 25-30, wherein said process comprises milling the hydrate of aripiprazole to a mean particle size of 20 .mu.m or less.

33. The hydrous aripiprazole according to claim 31, wherein said process comprises milling the hydrate of aripiprazole to a mean particle size of 20 .mu.m or less.

34. The hydrous aripiprazole according to claims 25-30, wherein said process comprises milling the hydrate of aripiprazole to a mean particle size of 36-14 .mu.m.

35. The hydrous aripiprazole according to claim 31, wherein the process comprises milling the hydrate of aripiprazole to a mean particle size of 36-14 .mu.m.

36. The hydrous aripiprazole according to any one of claims 25-30, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

37. The hydrous aripiprazole according to any one of claim 31, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

38. The hydrous aripiprazole according to claim 32, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

39. The hydrous aripiprazole according to claim 33, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

40. The hydrous aripiprazole according to claim 34, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

41. The hydrous aripiprazole according to claim 35, wherein the mean particle size is measured using a laser diffraction particle size analyzer.

42. The hydrous aripiprazole according to any one of claims 25-30, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

43. The hydrous aripiprazole according to any one of claim 31, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

44. The hydrous aripiprazole according to claim 32, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

45. The hydrous aripiprazole according to claim 33, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

46. The hydrous aripiprazole according to claim 34, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

47. The hydrous aripiprazole according to claim 35, wherein the mean particle size is measured using a laser diffraction particle size analyzer by suspending 0.1 g of said hydrous aripiprazole in a 20 mL n-hexane solution of 0.5 g soy lecithin.

48. A process for preparing hydrous aripiprazole wherein the process comprises milling a hydrate of aripiprazole having one or more of the following properties: a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree., 15.1.degree., 17.4.degree., 18.2.degree., 18.7.degree., 24.8.degree., and 27.5.degree. using a Cu K.sub..alpha. x-ray; and an endothermic curve comprising endothermic peaks at 75.0.degree. C., 123.5.degree. C. and 140.5.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min), to a mean particle size of 50 .mu.m or less.

49. The process according to claim 48, wherein said hydrate of aripiprazole has a powder x-ray diffraction spectrum comprising characteristic peaks at 2.theta.=12.6.degree., 15.1.degree., 17.4.degree., 18.2.degree., 18.7.degree., 24.8.degree., and 27.5.degree. using a Cu K.sub..alpha. x-ray.

50. The process according to claim 48, wherein said hydrate of aripiprazole has an endothermic curve comprising endothermic peaks at 75.0.degree. C., 123.5.degree. C., and 140.5.degree. C. in a thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min).

51. A process for preparing hydrous aripiprazole wherein the process comprises milling a hydrate of aripiprazole having one or more of the following properties: a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 7 using a Cu K.sub..alpha. x-ray; and an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 6; to a mean particle size of 50 .mu.m or less.

52. The process according to claim 51, wherein said hydrate of aripiprazole has a powder x-ray diffraction spectrum which is substantially the same as the powder x-ray diffraction spectrum shown in FIG. 7 using a Cu K.sub..alpha. x-ray.

53. The process according to claim 51, wherein said hydrate of aripiprazole has an endothermic curve which is substantially the same as the thermogravimetric or differential thermal analysis (heating rate 5.degree. C./min) curve shown in FIG. 6.

54. The process according to any one of claims 48-53, wherein the milling is performed by an atomizer using a rotational speed of 5000-15000 rpm for the main axis, a feed rotation of 10-30 rpm and a screen hole size of 1-5 mm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc